Effects of histone methyltransferase inhibition in endometriosis†

Colón-Caraballo M, Mariano Colón-Caraballo, Annelyn Torres-Reverón, John Lee Soto-Vargas, Steven L. Young, Bruce Lessey, Lessey B, Adalberto Mendoza, Mendoza A, Urrutia R, Raúl Urrutia, Flores I, Idhaliz Flores
Biology of reproduction · 2018 · vol. 99(2) , pp. 293–307 · doi:10.1093/biolre/ioy030 · PMID:29408993 · PMC6373837 · W2792091493
article OA: bronze CC0 ⤵ 25 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This study found that inhibiting EZH2 in endometriotic cells reduced H3K27me3 levels, migration, and proliferation, supporting its potential as a nonhormonal endometriosis treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Although the histone methyltransferase EZH2 and its product H3K27me3 are well studied in cancer, little is known about their role and potential as therapeutic targets in endometriosis. We have previously reported that endometriotic lesions are characterized by global enrichment of H3K27me3. Therefore, we aimed to (1) characterize the expression levels of EZH2 in endometriotic tissues; (2) assess H3K27me3 enrichment in candidate genes promoter regions; and (3) determine if pharmacological inhibition of EZH2 impacts migration, proliferation, and invasion of endometriotic cells. Immunohistochemistry of an endometriosis-focused tissue microarray was used to assess the EZH2 protein levels in tissues. Chromatin immunoprecipitation-qPCR was conducted to assess enrichment of H3K27me3 in candidate gene promoter regions in tissues. Immunofluorescence was performed to assess the effect of an EZH2-specific pharmacological inhibitor on H3K27me3 global enrichment in cell lines. To measure effects of the inhibitor in migration, proliferation, and invasion in vitro we used Scratch, BrdU, and Matrigel assays, respectively. Endometriotic lesions had significantly higher EZH2α nuclear immunostaining levels compared to eutopic endometrium from patients (glands, stroma) and controls (glands). H3K27me3 was enriched within promoter regions of candidate genes in some but not all of the endometriotic lesions. Inhibition of EZH2 reduced H3K27me3 levels in the endometriotic cells specifically, and also reduced migration, proliferation but not invasion of endometriotic epithelial cells (12Z). These findings support future preclinical studies to determine in vivo efficacy of EZH2 inhibitors as promising nonhormonal treatments for endometriosis, still an incurable gynecological disease.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Endometrium Enhancer of Zeste Homolog 2 Protein Adult Cell Line Cell Movement Cell Movement Cell Proliferation Cell Proliferation Endometriosis Endometriosis Endometrium Endometrium Endometrium Enhancer of Zeste Homolog 2 Protein Enzyme Inhibitors Enzyme Inhibitors Female Humans Indazoles

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (58)

Cited by (25)

Source provenance

europepmc
last seen: 2026-09-26T06:15:21.694264+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:20:01.354358+00:00
License: CC0 · commercial use OK